JP2022510964A5 - - Google Patents

Info

Publication number
JP2022510964A5
JP2022510964A5 JP2021531128A JP2021531128A JP2022510964A5 JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5 JP 2021531128 A JP2021531128 A JP 2021531128A JP 2021531128 A JP2021531128 A JP 2021531128A JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5
Authority
JP
Japan
Prior art keywords
seq
antigen
amino acid
binding molecule
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531128A
Other languages
English (en)
Japanese (ja)
Other versions
JP7637052B2 (ja
JP2022510964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067173 external-priority patent/WO2020132066A1/en
Publication of JP2022510964A publication Critical patent/JP2022510964A/ja
Publication of JP2022510964A5 publication Critical patent/JP2022510964A5/ja
Priority to JP2024192042A priority Critical patent/JP7882920B2/ja
Application granted granted Critical
Publication of JP7637052B2 publication Critical patent/JP7637052B2/ja
Priority to JP2026035546A priority patent/JP2026088139A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531128A 2018-12-19 2019-12-18 二重特異性抗cd28x抗cd22抗体及びその使用 Active JP7637052B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024192042A JP7882920B2 (ja) 2018-12-19 2024-10-31 二重特異性抗cd28x抗cd22抗体及びその使用
JP2026035546A JP2026088139A (ja) 2018-12-19 2026-03-05 二重特異性抗cd28x抗cd22抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781689P 2018-12-19 2018-12-19
US62/781,689 2018-12-19
PCT/US2019/067173 WO2020132066A1 (en) 2018-12-19 2019-12-18 Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192042A Division JP7882920B2 (ja) 2018-12-19 2024-10-31 二重特異性抗cd28x抗cd22抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022510964A JP2022510964A (ja) 2022-01-28
JP2022510964A5 true JP2022510964A5 (cg-RX-API-DMAC7.html) 2022-12-26
JP7637052B2 JP7637052B2 (ja) 2025-02-27

Family

ID=69182681

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531128A Active JP7637052B2 (ja) 2018-12-19 2019-12-18 二重特異性抗cd28x抗cd22抗体及びその使用
JP2024192042A Active JP7882920B2 (ja) 2018-12-19 2024-10-31 二重特異性抗cd28x抗cd22抗体及びその使用
JP2026035546A Pending JP2026088139A (ja) 2018-12-19 2026-03-05 二重特異性抗cd28x抗cd22抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024192042A Active JP7882920B2 (ja) 2018-12-19 2024-10-31 二重特異性抗cd28x抗cd22抗体及びその使用
JP2026035546A Pending JP2026088139A (ja) 2018-12-19 2026-03-05 二重特異性抗cd28x抗cd22抗体及びその使用

Country Status (16)

Country Link
US (3) US11396544B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897715A1 (cg-RX-API-DMAC7.html)
JP (3) JP7637052B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210104836A (cg-RX-API-DMAC7.html)
CN (1) CN113164598B (cg-RX-API-DMAC7.html)
AU (1) AU2019405747B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010238A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009004A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191580A1 (cg-RX-API-DMAC7.html)
IL (1) IL283945A (cg-RX-API-DMAC7.html)
MA (1) MA54540A (cg-RX-API-DMAC7.html)
MX (1) MX2021007497A (cg-RX-API-DMAC7.html)
MY (1) MY206140A (cg-RX-API-DMAC7.html)
PH (1) PH12021551401A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020132066A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119143875A (zh) * 2018-06-21 2024-12-17 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
KR20210104836A (ko) * 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
EP3941941A1 (en) * 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
JP7905328B2 (ja) 2020-09-18 2026-08-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Cd38及び/又はcd28を結合する抗原結合分子及びその使用
CN116635425A (zh) * 2020-11-03 2023-08-22 德国癌症研究中心公共法律基金会 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
EP4490192A1 (en) 2022-03-07 2025-01-15 Novimmune S.A. Cd28 bispecific antibodies for targeted t cell activation
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
AU2023254191A1 (en) * 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023198042A1 (zh) * 2022-04-11 2023-10-19 江苏恒瑞医药股份有限公司 特异性结合egfr和cd28的抗原结合分子及其医药用途
CN117264065B (zh) * 2022-06-15 2025-11-18 三优生物医药(上海)有限公司 一种her2抗原结合分子及其应用
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024077268A2 (en) * 2022-10-07 2024-04-11 Fred Hutchinson Cancer Center Human metapneumovirus antibodies and uses thereof
AU2023362569A1 (en) 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
JP2026508624A (ja) 2023-03-13 2026-03-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗cd22×抗cd28分子でがんを治療する方法
CN120904324A (zh) * 2024-04-30 2025-11-07 惠和生物技术(上海)有限公司 抗cd28抗体及其用途
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
US20260146100A1 (en) 2024-10-30 2026-05-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2008038587A1 (fr) 2006-09-25 2008-04-03 National University Corporation Nagoya University Lignée cellulaire du lymphome b malin modifié négativement par cd20
US20130079353A1 (en) 2009-12-22 2013-03-28 Karsten Gülow Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
KR102520731B1 (ko) 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2019315440B2 (en) * 2018-07-30 2025-03-13 Angeles Therapeutics, Inc. Improving the efficacy and safety of adoptive cellular therapies
CN109021114B (zh) * 2018-08-08 2020-06-09 武汉波睿达生物科技有限公司 联合两种单链抗体的双特异性嵌合抗原受体及表达载体
KR20210104836A (ko) * 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2022515611A5 (cg-RX-API-DMAC7.html)
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2021531005A5 (cg-RX-API-DMAC7.html)
FI3823664T3 (fi) Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä
JP2020528768A5 (cg-RX-API-DMAC7.html)
JP2017510559A5 (cg-RX-API-DMAC7.html)
JP2021524249A5 (cg-RX-API-DMAC7.html)
JP2023543152A5 (cg-RX-API-DMAC7.html)
JP2019107018A5 (cg-RX-API-DMAC7.html)
JP2021518103A5 (cg-RX-API-DMAC7.html)
JP2021524244A5 (cg-RX-API-DMAC7.html)
JP2014531201A5 (cg-RX-API-DMAC7.html)
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2013542194A5 (cg-RX-API-DMAC7.html)
JP2020514310A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2018519263A5 (cg-RX-API-DMAC7.html)
JP2018500014A5 (cg-RX-API-DMAC7.html)
JP2010513303A5 (cg-RX-API-DMAC7.html)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2023055904A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)